As states continue to consider proposals to curb spending on prescription drugs, “cost-effectiveness” reviews such as those conducted by the Institute for Clinical and Economic Review (ICER) are being considered as one method to determine treatment access and reimbursement. Pioneer Institute explores the potential impacts that ICER and other “one-size-fits-all” methods to healthcare value assessment could have for certain patient populations and medical innovation.
Get Updates on our Work to Protect Patients and Innovation!
Read Pioneer Institute Research:
Recent Media Coverage:
More Media Coverage:
March 17, 2020
March 3, 2020
The Washington Times: Americans stand to lose a lot with Medicare for All, especially children
November 14, 2019
October 16, 2019
October 3, 2019
San Francisco Examiner: ICER discriminates against people with rare diseases
TAKE ACTION TO PROTECT PATIENTS AND INNOVATION:
Click here to download our digital advocacy toolkit of social media, email, and website content resources to share information on how ICER threatens patients and innovation.
Read Research From Other Experts:
November 6, 2019
National Council on Disability (NCD): Quality-Adjusted Life Years and the Devaluation of Life with Disability
April 23, 2019
March 20, 2019